Page 159 of 1,034: studies 1,581 to 1,590 of 10,336, newest first. Back to the depression overview
JAMA Psychiatry December 1, 2023 Sanjay J. Mathew, Manish K. Jha, Amit Anand 8 citations
This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD).
Iranian Journal of Public Health December 1, 2023 Miaoxiong Yang, Baozhi Song, Yatao Jiang et al. 11 citations
We aimed to investigate the intervention effect of mindfulness-based interventions (MBIs) in patients with postpartum depression. The method of computer and manual keyword retrieval was used to search PubMed, Web of Science, Cochrane Library. Literature included in the study was assessed for quality and meta-analysis was performed using RevMan 5.3 software. Twelve articles were finally included...
medRxiv Preprint Server December 1, 2023 Brandon Taraku, Joana R Loureiro, Ashish K Sahib et al. 1 citation preprint
Dysfunctional reward processing in major depressive disorder (MDD) involves functional circuitry of the habenula (Hb) and nucleus accumbens (NAc). Ketamine elicits rapid antidepressant and alleviates anhedonia in MDD. To clarify how ketamine perturbs reward circuitry in MDD, we examined how serial ketamine infusions (SKI) modulate static and dynamic functional connectivity (FC) in Hb and NAc...
Psychological Medicine December 1, 2023 Paul McCrone, Henry Fisher, Clare Knight et al. 34 citations
There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper compares the cost-effectiveness of psilocybin-assisted psychotherapy (PAP) with conventional medication, cognitive behavioural therapy (CBT), and the combination of conventional medication and CBT. A decision model simulated patient events (response, remission, and...
Pharmacological Reports December 1, 2023 Magdalena Kolasa, Agata Faron-Górecka 18 citations
Treatment-resistant depression (TRD) is a subgroup of major depressive disorder in which the use of classical antidepressant treatments fails to achieve satisfactory treatment results. Although there are various definitions and grading models for TRD, common criteria for assessing TRD have still not been established. However, a common feature of any TRD model is the lack of response to at least...
Clinical Psychopharmacology and Neuroscience November 30, 2023 Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim et al. 16 citations
Previous studies suggested effectiveness of psilocybin in the field of mental health. FDA designated psilocybin as a "breakthrough therapy" for the treatment of treatment-resistant depression (TRD) in 2018. This paper provided a review of psilocybin's potential role in treatment of depression by focusing on published clinical trials. Studies showed that psilocybin, an agonist on 5-HT2A...
Proceedings of the National Academy of Sciences November 27, 2023 John H. Krystal, Alfred P. Kaye, Sarah J. Jefferson et al. 66 citations
Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and protection against relapse distinguish it from prior antidepressants. Its discovery emerged from a reconceptualization of the neurobiology of depression and, in turn, insights from the elaboration of its mechanisms of action...
Annals of General Psychiatry November 26, 2023 Giuseppe Maina, Marina Adami, Giuseppe Ascione et al. 56 citations
Abstract Background Treatment-resistant depression (TRD) is defined by the European Medicines Agency as a lack of clinically meaningful improvement after treatment, with at least two different antidepressants. Individual, familiar, and socio-economic burden of TRD is huge. Given the lack of clear guidelines, the large variability of TRD approaches across different countries and the availability...
JAAPA November 21, 2023 Elizabeth Boudreau, Krissa Orlowski
At the time this abstract was written, Elizabeth Boudreau was a student in the Medex Northwest PA program at the University of Washington School of Medicine. Krissa Orlowski is a part-time lecturer in the Medex Northwest PA program. The authors have disclosed no potential conflicts of interest, financial or otherwise.
International Journal of Social Science and Human Research November 17, 2023 Huong, Xuan Vu (PhD)
Major depressive disorder is a common and recurring condition that necessitates ongoing advancements in treatment. The integration of mindfulness meditation and cognitive behavioural techniques in mindfulness-based cognitive therapy (MBCT) has shown promise as an effective approach. This review focuses on the current evidence regarding MBCT's efficacy in treating acute depression and preventing...